ANP – Morgans rates the stock as Add

By Broker News | More Articles by Broker News

Over the next six months, Morgans expects catalysts to de-risk the regulatory pathway and build upon a strong business case for global pharma interest.

The third quarter cash flow report showed Morgans there’s sufficient cash to see out a number of these catalysts in the short term. The Speculative Buy and $0.38 target price are maintained.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

 

Target price is $0.38.Current Price is $0.21. Difference: $0.17 – (brackets indicate current price is over target). If ANP meets the Morgans target it will return approximately 81% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

 

RELATED COMPANIESTagged

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →